Therapy-resistant and -sensitive lncRNAs, SNHG1 and UBL7-AS1 promote glioblastoma cell proliferation

Figure 1

Dysregulated lncRNAs in various brain tumors compared with normal brain tissues. (a) Venn diagram showing dysregulated lncRNAs by1.0-fold or greater (p <0.05) in brain tumors such as ependymoma (n =46), glioblastoma (n =34), medulloblastoma (n =22), and pilocytic astrocytoma (n =15) compared with control brain tissues (n =13) from dataset GSE50161. (b) (A-O) Heatmap illustrating the expression (average log expression value) of the dysregulated lncRNAs between indicated brain tumor and normal brain samples in a. (a and b-A, C, D, N) The expressions of 31, 13, 18, and 27 lncRNAs were exclusively dysregulated in ependymoma, GBM, PA, and medulloblastomas tumors, compared with control samples, respectively. (a and b-B, E, G, H, J, O) The expressions of 14, 10, 7, 2, 15, and 7 lncRNAs were dysregulated in both ependymoma and GBM; ependymoma and PA; GBM and PA; PA and medulloblastomas; ependymoma and medulloblastomas; GBM and medulloblastomas; compared with control samples, respectively. (a and b-F, I, K) The expressions of 20, 8, and 12 lncRNAs were dysregulated in ependymoma, GBM and PA; ependymoma, PA and medulloblastomas; GBM, ependymoma and medulloblastomas, compared with control samples, respectively.

(a)

(b)